Readmission prevention
Most deterioration after discharge goes unseen until it becomes a readmission. Objective monitoring catches the drift in time to act, worth roughly $15,200 for every readmission you avoid.
For Payers and Health Plans
Stop paying for therapy that is not working.
Industry estimates put roughly 16% of U.S. health spend, about $528 billion a year, on non-optimized therapy. Bardel shows you, in real time, which treatments are working and which are not, so your dollars follow the response.
The cost of not knowing
You reimburse the treatment. No one tells you whether it worked.
A claim confirms a therapy was paid for. It never tells you whether the patient responded. So the same dollars keep flowing into care that is not moving the outcome, and the failures surface later as readmissions, escalations, and avoidable spend you could have seen coming.
$528B
spent each year on non-optimized therapy, roughly 16% of U.S. health spend (industry estimate)
$15,200+
the cost of a single avoidable readmission (industry estimate)
$30K-$40K
per patient each year when a biologic is escalated, often without proof the prior step failed
How it works
One platform turns the body's response into the signal your contracts have been missing.
Bardel reads the physiological signal others miss from devices your members and hospitals already use, then turns it into an objective, real-time read of whether a treatment is working. The same five steps that earn clinics revenue give you the visibility to fund only the care that performs.
1
Capture
Read the response from the monitors, watches, and phones your members already use. No new hardware to fund.
2
Measure
Turn that signal into an objective treatment-response read, in real time, between visits.
3
Match
Surface strong responders, moderate responders, non-responders, and adverse cases so dollars follow what works.
4
Verify
Tie every covered decision to objective data and a complete audit trail you can stand behind.
5
Save
Catch the expensive failures before they happen, and share the savings on a model that aligns both sides.
Same engine, your language. Steps 4 and 5 are Bardel's canonical Bill and Learn: the reimbursable monitoring that earns clinics revenue is the audit trail that lets you verify, and the dataset that compounds with every session is what helps you save.
The phenotype is the constant. Everything else is configuration. Read the response, and you can read whether any treatment is worth what you are paying for it.
Where it pays off first
Three places measurement turns directly into savings.
Smarter escalation spend
Before funding an expensive therapy escalation, see whether the prior treatment truly failed, or was simply not working for reasons a claim could never surface in time to change the call.
Risk stratification
Stratify members by objective treatment response, not claims history alone, then steer case management toward the patients who are not responding and driving the most avoidable cost.
The model
Aligned incentives. You win when the spend gets smarter.
Bardel is designed not to be another cost center. The model is shared savings: Bardel surfaces the therapy that is not working, you redirect the dollars, and Bardel is paid out of the savings it helps create. The incentives line up because both sides win only when the spend gets smarter.
A shared-savings model
Bardel is paid out of the waste it helps you remove, never added on top of it. When your spend gets smarter, so does the return.
Prevent the expensive failures
Catch non-response early and head off the readmissions and escalations before they become your highest-cost claims.
Verify what you cover
Objective risk stratification plus a complete audit trail. Every covered decision is backed by data, not by a recalled pain score.
Paying without measurement
- Claims confirm therapy was paid for, never that it worked.
- Non-response surfaces late, as a readmission or an escalation.
- The same dollars keep funding care that is not moving the outcome.
- Coverage decisions rest on subjective reports and recall.
Paying with Bardel
- Objective response data behind every covered treatment.
- Non-responders flagged in real time, before the costly failure.
- Dollars follow what works, with savings shared on aligned terms.
- A complete audit trail stands behind every decision.
Advised by payer leadership
Built with people who have run the P&L.
Bardel's payer strategy is shaped by Nancy Cocozza, former President of the Aetna Medicare Division, where she ran a P&L of roughly $23 billion. The shared-savings model is designed by someone who has sat on your side of the table.
Covered population
By objective treatment response
Strong responders
Keep funding what works
Moderate responders
Watch the trajectory
Non-responders
Redirect before it compounds
Adverse cases
Intervene early
Spend you can redirect
Illustrative. Every band carries a complete audit trail.
Decades
of peer-reviewed cardiac research
0+
therapeutic sessions captured to date, as of 2026
0
devices live across 33 states
0%
monthly retention, so the response data keeps coming in
Pay for what works. Stop paying for what does not.
See how the shared-savings model maps to your book, and what real-time response data does to your highest-cost events.